Caris Life Sciences Partnership

Caris Life Sciences Partnership

Caris Life Sciences®, a leading biotechnology company focused on fulfilling the promise of precision medicine, appointed the Barbara Ann Karmanos Cancer Institute as a center of excellence site in the Caris Centers of Excellence (COE) for Precision Medicine Network™. As a network member, Karmanos will actively participate in the development of standards of care and best practices for integrating and using tumor profiling to increase patient access to personalized medicine in clinical settings.

Gerold Bepler, M.D., Ph.D., president and CEO of Karmanos, has been appointed vice chairman of the network to help guide the development of standards for tumor profiling and research protocols integrating tumor profiling.

Caris Molecular Intelligence®

Karmanos will leverage Caris’ multiple‐technology tumor profiling service, Caris Molecular Intelligence®, to enable the practice of precision medicine, advance research through clinical trials, help guide therapy decisions and identify clinical trial opportunities based on each patient’s unique tumor biology.

Caris Molecular Intelligence is a service that correlates molecular data from a tumor with biomarker and drug associations from the latest clinical and scientific cancer literature. It is the key technology platform used across the network to enable the delivery of precision medicine.  This information is used to help inform treatment decisions by identifying therapies that have the potential to be most effective and to rule out those that are less likely to work based on the unique molecular characteristics of an individual patient’s cancer. The Caris Molecular Intelligence system uses multiple technology platforms combined with sophisticated bioinformatics to develop clinically actionable reports for more than 70,000 patients to date.

Enhanced Patient Care

This partnership represents an unparalleled opportunity for our patients to benefit from molecular profiling, which has become a crucial part of cancer care.

  • Examines a person’s genes at the molecular level to better understand why various gene mutations cause certain cancers in certain people.
  • Advanced tumor profiling technologies help to better assist physicians with their approach to cancer diagnosis and treatment, especially for rare and aggressive cancers 
  • Allows Karmanos physicians to more precisely tailor treatments to a patient’s particular cancer.
  • Enhances Karmanos' clinical trials program.

About Caris Life Sciences®

Caris Life Sciences® is a leading biotechnology company focused on fulfilling the promise of precision medicine through quality and innovation. Caris Molecular Intelligence®, the company’s healthcare information and comprehensive tumor profiling service with more than 70,000 patients profiled, provides oncologists with the most potentially clinically actionable treatment options available to personalize cancer care today. Using a variety of advanced profiling technologies to assess relevant biological changes in each patient’s tumor, Caris Molecular Intelligence connects biomarker data generated from a tumor with biomarker-drug associations supported by evidence in the relevant clinical literature. Since 2009, Caris has tracked clinical and outcome data for certain patients undergoing tumor molecular profiling, for which Caris has observed that patients treated with drugs consistent with their molecular profile show a significant increase in overall survival. The company is developing its Carisome® TOP™ technology, a revolutionary and proprietary blood-based platform for the development of novel therapeutics, drug delivery and drug target identification. The technology is also being developed for diagnosis, prognosis, and theranosis of cancer and other complex diseases. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout Europe, the U.S., Australia and other international markets. To learn more, please visit www.CarisLifeSciences.com . 

The Latest From Karmanos Cancer Institute

News

McLaren Proceedings: Community

McLaren — We are our community To the communities we’re privileged to serve, McLaren is more than hospitals and off-site facilities. McLaren is th...

Read More

IN THE NEWS: The 5 best ways to slash your liver cancer risk, according to doctors

Best Life Liver cancer can be difficult to detect. Anthony Shields, M.D., Ph.D. , medical oncologist, leader of the Gastrointestinal and Neuroendo...

Read More

SoftVue(TM): Additional Screening Option for Women with Dense Breasts

WJR Natasha Robinette, M.D. , radiologist and clinical service chief of imaging at Karmanos Cancer Center , speaks with WJR's Lloyd Jackson about ...

Read More
News

SoftVue(TM): Additional Screening Option for Women with Dense Breasts | WJR's The Guy Gordon Show

Listen Now

ACS CAN Michigan Candid Connection, June 2022 - Cancer Survivorship

Listen Now

How a preemptive cancer screening helped save this doctor’s life

Listen Now